STEREOTACTIC Revenue and Competitors
Estimated Revenue & Valuation
- STEREOTACTIC's estimated annual revenue is currently $3.8M per year.
- STEREOTACTIC's estimated revenue per employee is $100,000
Employee Data
- STEREOTACTIC has 38 Employees.
- STEREOTACTIC grew their employee count by -3% last year.
STEREOTACTIC's People
Name | Title | Email/Phone |
---|
STEREOTACTIC Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.8M | 69 | 5% | N/A | N/A |
#2 | $20.1M | 146 | 7% | N/A | N/A |
#3 | $1.1M | 15 | -21% | N/A | N/A |
#4 | $3.6M | 36 | 6% | N/A | N/A |
#5 | $3.4M | 34 | -8% | N/A | N/A |
#6 | $1.9M | 22 | 0% | N/A | N/A |
#7 | $4.3M | 43 | -2% | N/A | N/A |
#8 | $2.1M | 24 | -23% | N/A | N/A |
#9 | $12M | 96 | 7% | N/A | N/A |
#10 | $1.4M | 18 | 6% | N/A | N/A |
What Is STEREOTACTIC?
360 marketing. Ad agency (online and offline). Video Production. Working in Russia and across the globe www.stereotactic.ru
keywords:N/AN/A
Total Funding
38
Number of Employees
$3.8M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
STEREOTACTIC News
2022-04-13 - Stereotactic Body Radiotherapy Is a Viable Option for ...
Treatment with stereotactic body radiotherapy (SBRT) appears to be a reasonable option for patients with impaired pulmonary function and...
2022-04-13 - Dosimetry audit on stereotactic radiosurgery applications ...
This webinar presents a novel methodology for dosimetry audits on intracranial stereotactic radiosurgery applications. The succeSRS dosimetry...
2022-03-30 - Magnetic Resonance Imaging-Guided Online Adaptive Lattice ...
Magnetic Resonance Imaging-Guided Online Adaptive Lattice Stereotactic Body Radiotherapy in Voluminous Liver Metastasis: Two Case Reports.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.2M | 38 | 0% | N/A |
#2 | $2.2M | 38 | 9% | N/A |
#3 | $3.9M | 39 | 63% | N/A |
#4 | N/A | 39 | 8% | N/A |
#5 | $4M | 40 | 5% | N/A |